The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy

Current Eye Research

Volumn 32, Issue 12, 2007, Pages 1037-1043

  Sharpe, Elizabeth D ^a   Reynolds, Adam C ^b   Skuta, Gregory L ^b   Jenkins, Jessica N ^c   Stewart, William C ^d,e,f  

^a Glaucoma Consultants   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Charleston Research Company LLC   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e University of South Carolina   (United States)

^f NONE   (United States)

Author keywords

Bimatoprost; Incidence; Latanoprost; Periocular pigmentation; Reversibility

Indexed keywords

BIMATOPROST; LATANOPROST; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; LIPID; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG INDICATION; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PIGMENT DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; EYE COLOR; EYELID DISEASE; INTRAOCULAR HYPERTENSION; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; SKIN PIGMENTATION;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; EYE COLOR; EYELID DISEASES; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PIGMENTATION DISORDERS; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; SKIN PIGMENTATION; TONOMETRY, OCULAR;

EID: 39149126689     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701750625     Document Type: Article

References (25)

1. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
2. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
3. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
4. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566-2573.
5. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001;131:798-799.
6. Susanna R Jr, Giampani J Jr, Borges AS, Vessani RM, Jordao ML. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259-263.
7. Parrish RK, Palmberg P, Sheu W-P, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003;135:688-703.
8. Dubiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol. 2002;45:S353-S360.
9. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
10. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
11. Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262-266.
12. Stewart WC. Prostaglandin analogues: Their usage and benefits in glaucoma treatment. Ophthalmic Practice, 1996;14:48-55.
13. Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001;119:614-615.
14. Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2003;135:713-715.
15. Sodhi PK, Verma L, Ratan SK. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2004;137:783.
16. Book SA. Essentials of Statistics. New York: McGraw-Hill, 1978.
17. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol. 2002;86:1085-1088.
18. Chiba T, Kashiwagi K, Ishijima K, Furuichi M, Kogure S, Abe K, Chiba N, Tsukahara S. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004;48:141-147.
19. Chou SY, Chou CK, Kuang TM, Hsu WM. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye. 2005;19:7684-7687.
20. Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47 Suppl 1:S162-S175.
21. Albert DM, Gangnon RE, Zimbric ML, Damico CM, Fisher MR, Gleiser J, Grossniklaus HE, Green WR. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004;122:1680-1685.
22. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122:957-965.
23. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547.
24. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
25. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361-S368.